A major milestone for Thai public health! The Government Pharmaceutical Organization (GPO) teams up with Chulalongkorn University Faculty of Medicine and U.S. partners to developa "Personalized Cancer Vaccine"which has begun Phase 1 human trials showing safe, highly effective results that increase survival chances and reduce treatment costs by five times.
Cancer remains a leading cause of death, causing great concern among patients and families. Recently, Thai medical science sparked major hope as the GPO and U.S.-based Seqker Biosciences Inc. collaborated to developa "Personalized Cancer Vaccine"(Therapeutic, Personalized Cancer Neoantigen Vaccine) with academic and medical cooperation from Chulalongkorn University Faculty of Medicine.
This new cancer treatment technology is driven by the concept of"Precision Medicine"which differs entirely from traditional treatments. Doctors analyze each patient's tumor tissue to decode the cancer cells’ genetic mutations, identify specific antigens, and then design and synthesize a vaccine that maximally stimulates the immune system to precisely recognize and destroy cancer cells without harming surrounding healthy cells.
According to the latest progress presented at the GPO Pharmaceutical Summit, early clinical research (SQK01 Phase Ib Trial, reference codes NCT06614140 and NCT07002203) demonstrates tangible success, showing thatthe "Personalized Cancer Vaccine"is highly safe and effectively stimulates immune responses against solid tumors.
Furthermore, when combined with"immunotherapy drugs"for 5 months, the treatment showed promising statistics that offer great hope for patients, including
These results prove this innovation is not just theoretical but significantly extends life expectancy and improves quality of life for cancer patients.
Producing this type of vaccine involves complex processes and advanced bioinformatics technology, divided into five main steps as follows:
This technology has been tested abroad on various cancers such as skin, kidney, lung, and pancreatic cancers. In Thailand, clinical trials have begun with breast, stomach, and colorectal cancer patients, which are among the leading cancers causing Thai deaths.
A key advantage is"increased access to treatment"because the entire process—from genetic decoding to vaccine production—is done domestically. This reduces treatment costs by 4 to 5 times compared to traveling abroad for treatment or importing vaccines from Europe or the U.S. This is a crucial step toward making this world-changing innovation more accessible to Thai people in the future.
Although the personalized cancer vaccine is still under clinical research and evaluation, the project allows qualified patients to apply. Interested individuals must undergo thorough assessment and screening by cancer specialists from the project’s network hospitals.
If you or someone close to you is a cancer patient interested in participating, you can contact and inquire officially via:
This medical advancement shows Thailand is ready to become a future center for precision medicine and offers new hope to help cancer patients regain a brighter life.